Goldman Sachs Starts Biohaven Pharmaceutical Holding (BHVN) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $70 at Needham & Company
May 8, 2019 7:24 AM EDTNeedham & Company analyst Alan Carr raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $70.00 (from $56.00) while maintaining a Buy rating.
Carr commented, "Biohaven reported 1Q19 financial results and hosted an investor event at AAN mtg yesterday. Pre-NDA mtgs have been completed... More
